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Over the years, IVF/ICSI protocols have continued to evolve with efforts to improve outcomes. As a result, treatment
success may be related to certain procedural factors, including number of embryos transferred and stage at which
they are transferred. This review aims to assess the safety and effectiveness of IVF/ICSI in comparison to
spontaneous conception and less invasive ARTs and the impact of procedure-related factors on the outcomes
of IVF/ICSI in order to support the development of local clinical and policy guidance. Following Cochrane
Collaboration guidelines and the PRISMA statement, a comprehensive systematic review of literature examining
the impact of procedural characteristics on the safety or effectiveness of IVF/ICSI from 2007 to date was performed.
33 systematic reviews and 3 primary studies evaluating the impact of procedural differences, IVF/ICSI in comparison to
less invasive ARTs, and ARTs in comparison to spontaneous conception were found. IVF was shown to offer significant
benefits over no treatment and IUI in achieving pregnancy and live birth among couples with endometriosis or
unexplained infertility. Frozen and blastocyst-stage embryo transfers were as effective as fresh and cleavage-stage
embryo transfers, respectively. In comparison to single embryo transfer, double embryo transfer significantly increased
pregnancy, live birth and multiple pregnancy/birth rates. IVF/ICSI was associated with more complications during
pregnancy and delivery, and in infants compared to naturally conceived pregnancies, particularly when multiple
embryo transfer was used. Frozen embryo transfer had fewer adverse events during pregnancy and delivery than fresh
embryo transfer, and was at least as safe in terms of infant outcomes. The potential complications of IVF/ICSI may be
minimized through procedural choices, but such choices often impact effectiveness. Thus, in developing clinical and
policy guidance around IVF/ICSI, the risk-benefit trade-offs patients and providers are willing to accept must be
carefully considered.
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Infertility is a reproductive disorder defined clinically as
the failure to achieve a clinical pregnancy following at
least 12 months of unprotected sexual intercourse [1-3].
It can be related to female factors (35% to 40% of cou-
ples), male factors (20× to 40% of couples), both (20% to
30% of couples), or remain unexplained [4-6]. In women,
it is commonly caused by ovulatory dysfunction, tubal
obstructions, and/or endometriosis. In men, it is often a* Correspondence: alexan@ualberta.ca
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unless otherwise stated.result of abnormalities in sperm production and function
or sperm duct blockages.
Management includes fertility counselling, lifestyle
modifications, medical/surgical treatment of underlying
conditions, fertility medications, and assisted reproduct-
ive technologies (ARTs), such as intrauterine insemin-
ation (IUI) and in vitro fertilization (IVF)/intracytoplasmic
sperm injection (ICSI). In recent years, efforts to optimize
maternal and infant outcomes have focused on IVF/ICSI
and specific procedure-related factors, such as the number
of embryos transferred and whether sperm, eggs or em-
bryos used should be fresh or frozen [7-10].
Parallel to these developments in technological innovation,
governments in many countries have been facing demandsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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as to reduce adverse events and complications and im-
prove maternal and child outcomes. In particular, in the
province of Alberta, the government has been considering
options for the public funding of IVF. This has necessi-
tated the examination of evidence relating to the safety
and effectiveness of existing ARTs services (which are cur-
rently paid for out-of-pocket), and of the procedure-related
factors relevant to these services, in order to inform the
development of public policy options.
The objective of this review was to determine the
current state of the science related to the safety and effect-
iveness of IVF/ICSI in comparison to natural conception
and less invasive ARTs that are available in the province
and the influence of procedure-related factors on the
safety and effectiveness of IVF/ICSI.
Methods
A systematic review of relevant published systematic re-
views and primary studies (when systematic reviews
were not available) addressing the safety and effective-
ness of IVF/ICSI in comparison to natural/spontaneous
conception (SC) and less invasive ARTs and the impact
of key procedure-related factors on the safety and clin-
ical effectiveness of IVF/ICSI) was performed following
Cochrane Collaboration guidelines and the PRISMA
statement [11,12].
Currently, the ARTs services available in Alberta are:
ovulation induction, IUI, and IVF/ICSI. Based on these,
and a recent review of IVF funding policies around the
world, 2 important comparisons of procedures were
identified for review: 1) IVF/ICSI in comparison to SC,
and 2) IVF/ICSI in comparison to less invasive ARTs
(ovulation induction and IUI) [13]. In addition, 4 com-
parisons of different factors associated with IVF/ICSI
were also identified: 1) single versus multiple embryo
transfers in IVF/ICSI, 2) fresh versus frozen embryo trans-
fers, 3) blastocyst versus cleavage stage embryo transfers,
and 4) autologous versus donor embryo transfers. The
current review focuses on the impact of each of these
factors on the: 1) safety of IVF/ICSI, including pregnancy/
delivery (obstetrical) complications (ectopic pregnancy,
gestational diabetes, preeclampsia, placental complications,
preterm birth, and caesarean delivery) and neonatal/infant
complications (low birth weight, neonatal or perinatal
mortality, neonatal intensive care unit admissions, birth
defects and congenital malformations), and 2) the effect-
iveness of IVF/ICSI, including rates of cycle cancellation,
pregnancy, miscarriage, live birth and multiple pregnancy/
birth. At the first stage, a search for systematic reviews
synthesizing primary studies was conducted. A review of
additional primary studies was also planned as a second
stage if no existing published review on the outcomes of
interest for any comparison was found. Details of theidentification and selection of information sources (in-
cluding eligibility criteria) are provided below.Identification and selection of relevant papers
Stage 1: identification of systematic reviews
A literature search for systematic reviews describing the
safety or effectiveness of IVF/ICSI published in English
within the last 5 years was conducted. A structured search
strategy, which combined relevant controlled vocabulary
terms, such as Medical Subject Headings (e.g., Reproductive
Techniques, Assisted; Fertilization in Vitro; Embryo
Transfer) with additional non-index keywords (e.g., assisted
reproduct*; IVF), was developed and then applied to the
following bibliographic databases: PubMed (MEDLINE
and non-MEDLINE sources), EMBASE, The Cochrane
Library, the Centre for Reviews & Dissemination (DARE,
NHS EED, and HTA databases), Web of Science, Scopus,
CINAHL, and PsycINFO. The search was performed
in January 2012 and updated monthly until March 2013.
The selection criteria (including the PICO questions) for
reviews found at this stage are provided in Table 1. Any
systematic review that included patients 18 years or older
with infertility undergoing IVF/ICSI or one of the com-
parator interventions listed in Table 1 were included.
Through this process, no systematic reviews were found
that assessed the impact of: 1) IVF/ICSI (versus SC) on
multiple pregnancy/birth rates, 2) less invasive ARTs (ver-
sus IVF/ICSI) on neonatal/infant complications, 3) the
state of embryos (fresh or frozen) on multiple pregnancy/
birth rates, 4) the stage of embryos (blastocyst or cleavage)
on pregnancy/delivery complications or neonatal/infant
complications, and 5) the source of embryos (autologous
or donor).
To identify unpublished evidence, Google, grey litera-
ture databases, and web sites of guidelines, clinical trials,
health technology assessment agencies, and key ARTs-
related international and national organizations were
searched. In addition to the electronic searches, the ref-
erence lists of relevant articles were scanned and clinical
experts in Alberta were contacted. Search results were
imported into Reference Manager and duplicate citations
were removed. The details of the literature search are
provided in Additional file 1: Table S1.Stage 2: identification of primary studies
Based on the predefined comparisons and outcomes of
interest described above, available evidence from the in-
cluded systematic reviews was assessed to identify any
evidence gaps. Since no systematic reviews for some
comparisons (as described in the next section) were
found, an additional search for primary studies was per-
formed. A structured search strategy similar to that used
to search for reviews as described above was applied to
Table 1 PICOS elements of the review protoco
Parameter Inclusion criteria Exclusion criteria
Participants • Couples 18 years of age and older with infertility
Interventions • IVF/ICSI • GIFT/ZIFT
• In vitro maturation
Comparators • Spontaneous/natural conception Studies comparing different drugs or drug regimens used
• Less invasive ARTs (ovulation induction, intrauterine
insemination)
• Studies assessing pre-treatment characteristics, such as embryo
and uterine preparation techniques or hysteroscopy, or treatment
‘add-ons’, such as preimplantation genetic screening (PGS) or
assisted hatching (AH)
• Procedural differences, including:
- the number of embryo’s transferred
- blastocyst vs. cleavage embryo transfers
- frozen vs. fresh embryo transfers
- autologous vs. donor embryo transfers
Outcomes Safety: • Studies without any defined clinical outcomes
• Neonatal/infant complications (e.g., ectopic pregnancy,
low birth weight, neonatal/perinatal mortality, birth defects,
congenital malformations)
• Pregnancy and delivery complications (e.g., OHSS, ectopic
pregnancy, preeclampsia, caesarean delivery, preterm birth)
Effectiveness:
• Indicators of cycle success (e.g., number of oocytes
retrieved, cycle cancellation, implantation)
• Pregnancy, miscarriage, live birth
• Multiple pregnancy/multiple birth
Study design • Systematic reviews Primary studies*
*Primary studies will be included if evidence gaps are identified after review of systematic reviews.
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March 2013 (see Additional file 1: Table S1).
The titles and abstracts of all search results were inde-
pendently reviewed by two researchers using a standard
checklist with predetermined study inclusion and exclu-
sion criteria (see Table 1 for a list of inclusion/exclusion
criteria). Disagreements were resolved through discus-
sion and third party review. Concordance between re-
searchers was assessed using the Kappa statistic [14].
Data extraction and critical appraisal of included papers
Each researcher independently extracted information
from selected reviews and primary studies using a stand-
ard, pre-tested data abstraction form and a set of decision
rules. The form contained elements for assessing the pur-
pose, methods, findings, and quality of each paper. The
quality of each systematic review was determined using
the Oxman and Guyatt index of scientific quality scoring
system for systematic reviews [15,16], a widely validated
scale. For primary studies, each was critically appraised
using the Oxford Levels of Evidence Scale [17]. The over-
all quality of evidence was assessed using the GRADE
approach [18].Synthesis of results
Information collected from the systematic reviews and
primary studies were summarized in tables to facilitate
comparative analyses of any variations in methodo-
logical parameters. The findings were then used to exam-
ine heterogeneity across papers and determine whether
meta-analyses were feasible. Where clinical heterogeneity
precluded presentation of pooled estimates, the results
from papers were summarized qualitatively. Given the
heterogeneity between studies, a meta-analysis was not
performed.
Results
Results of literature search
1,733 discrete citations were identified through the lit-
erature search for systematic reviews, of which 79 poten-
tially relevant systematic reviews were selected for full
review (Figure 1). Thirty-three met the inclusion criteria.
The search for additional primary studies yielded 4,614
discrete citations (Figure 2). Three potentially relevant
studies were selected for full review, all of which met the
inclusion criteria. Excluded studies and their reasons for
exclusion are presented in Additional file 2: Table S2.
Figure 1 PRISMA flowchart of literature search results and study selection for safety and clinical effectiveness review: systematic reviews.
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included study are summarized in Additional file 3: Table
S3, Additional file 4: Table S4, Additional file 5: Table S5;
Additional file 6: Table S6, Additional file 7: Table S7,
Additional file 8: Table S8, Additional file 9: Table S9,
Additional file 10: Table S10, Additional file 11: Table
S11, Additional file 12: Table S12, Additional file 13:Figure 2 PRISMA flowchart of literature search results and study sele
primary studies.Table S13, Additional file 14: Table S14, Additional
file 15: Table S15 and Additional file 16: Table S16.
Overall description of included studies
Three primary studies and 33 systematic reviews, of
which, 24 included meta-analyses, were included. As de-
scribed below, they evaluated the safety and effectivenessction for safety and clinical effectiveness review: additional
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and the effect of the number, stage (blastocyst or cleav-
age), state (fresh or frozen) and source (autologous or
donor) of embryos transferred on the safety and effect-
iveness of IVF/ICSI (see Table 2).
IVF/ICSI in comparison to SC
In 17 of the reviews, ARTs was compared to SC (i.e., con-
ception not preceded by an ARTs intervention) [19-35].
Among them, 11 also presented pooled estimates from
quantitative analyses of at least one of the outcomes. The
majority of studies comprising the reviews were retrospect-
ive or prospective cohorts with the general population
serving as the ‘control’ group, rather than infertile couples
who had eventually achieved pregnancy without the use of
assisted conception. Of the 17 reviews, 1 reported preg-
nancy and live birth rates, 6 reported pregnancy/delivery
complications and 15 reported neonatal/infant complica-
tions, focusing on short- and long term infant outcomes,
ranging from neonatal periods through infancy and child-
hood. Outcomes at adolescence and adulthood were
examined in 6 reviews. Population and procedural charac-
teristics were rarely reported. No reviews or additional
primary studies reporting on the effect of IVF/ICSI on
multiple pregnancy birth rates were found.
IVF/ICSI in comparison to less invasive ARTs treatment
options
IVF/ICSI was compared to less invasive ARTs in 1 meta-
analysis and 1 review [31,36]. The meta-analysis comprised
6 RCTs (published 1993 to 2011) comparing OHSS, preg-
nancy, multiple pregnancy and live birth rates after IVF/
ICSI versus IUI (4) or SC (2) [31]. Where RCTs reported
treatment protocols, IVF/ICSI was preceded by a GnRHa
protocol with hMG or FSH and involved the transfer of
1–4 blastocyst or cleavage stage embryos, whereas clomi-
phene citrate (CC) or gonadotropins (e.g., FSH) were used
for controlled ovarian stimulation (COS) in IUI. In 3 of
the 4 comparing IVF/ICSI to IUI, women who had not
previously received ARTs underwent: 1) up to 2 cycles of
IVF (1 fresh cycle and 1 frozen-thaw cycle) vs. up to 3 cy-
cles of IUI, 2) up to 6 cycles of IVF vs. up to 6 cycles of
IUI, or 3) 1 cycle of IVF vs. up to 3 cycles of IUI. In the
fourth study, all couples received up to 3 cycles of IUI
with CC as a first line of treatment. Women who failed to
achieve an ongoing pregnancy after these 3 cycles under-
went either: 1) up to 6 cycles of IVF, or 2) up to 3 cy-
cles of IUI with FSH and, if no pregnancy is achieved
with FSH-IUI, up to 6 cycles of IVF.
The review that did not contain a meta-analysis in-
cluded 47 primary studies (mostly case–control and co-
hort studies) examining pregnancy complications after
different types of ARTs. However, no further details of
these studies were provided [36]. No reviews or additionalprimary studies reporting neonatal/infant complications
after IVF/ICSI in comparison to less invasive ARTs were
found.
Number of embryos transferred
Six meta-analyses spanning a total of 25 unique primary
studies (14 RCTs, 1 quasi-RCT, and 10 cohort studies
published between 1994 and 2010) evaluated the effect
of the number of embryos transferred on the safety and
effectiveness of IVF/ICSI [30,37-41]. One review evalu-
ated the association between fresh, autologous IVF/ICSI
and several patient and procedural factors pre-identified
as predictors of IVF/ICSI success, one of which was the
number of embryos transferred [41]. One review evalu-
ated the association between fresh, autologous IVF/ICSI
and several patient and procedural factors pre-identified
as predictors of IVF/ICSI success [41]. A total of 14
studies were included, mainly retrospective cohorts,
published between 1997 and 2008. The number of em-
bryos transferred was assessed in 7 studies and the
quality of embryos transferred in 3 studies. In one meta-
analysis, individual patient data were used [37]. Five
meta-analyses compared double embryo transfer (DET)
to elective single embryo transfer (eSET), and one also
assessed higher order multiple embryo transfers and lim-
ited analyses to fresh embryos only. Three excluded
blastocyst-stage embryos, and one excluded donor oo-
cytes or embryos, although the use of donors was not
explicitly stated in any of the pooled studies. Across
these studies, similar COS protocols had been used
(GnRHa + hMG or FSH), and most only included one
cycle of IVF/ICSI per couple. Over half specified mater-
nal upper age limits (ranging from 30 to 37 years) and 7
of them further limited inclusion to women deemed to
have a “good prognosis” (i.e., younger women in their
1st-2nd IVF/ICSI cycle with good embryo quality).
Fresh versus frozen embryo transfer (FET)
The safety and effectiveness of FETs compared to fresh
embryo transfers was assessed in 5 reviews of 83 unique
primary studies published between 1993 and 2011
[42-46]. Four also presented meta-analyses. However,
one was based on a single study and another focused ex-
clusively on the incidence of ectopic pregnancy [42].
The remaining two assessed the effect of FET on preg-
nancy and miscarriage (3 RCTs), and maternal and in-
fant safety in singleton pregnancies (11 cohorts) [45,46].
Where reported, included studies used similar COS pro-
tocols (GnRHa + hMG and/or FSH in the majority), and
evaluated autologous cleavage- and blastocyst-stage em-
bryo transfers in ‘unselected’ women (all women receiv-
ing fertility treatment in a certain area or clinic) or
women expected to have a good prognosis. The fifth re-
view, which did not perform a meta-analysis, assessed 67
Table 2 Assessment of available evidence: number of included systematic reviews and primary studies and GRADE rating of quality of evidence for predefined












(6 reviews; no additional
primary studies)
State of embryos –
fresh/frozen
(5 reviews; no additional
primary studies)
Stage of embryos –
blastocyst/cleavage
(5 reviews; 2 additional
primary studies)
Source of embryos –
autologous/donor 1 review;
1 additional primary study)
Effectiveness:
• Cycle success (cancellation,
implantation)
* * 2 reviews * 2 reviews *
Low to Moderate Moderate
• Pregnancy, miscarriage, and
live birth
1 review 1 review 6 reviews 2 reviews 2 reviews 1 primary study
Moderate Moderate Low to Moderate Low to Moderate Moderate Low
• Multiple pregnancy/birth * 1 review 3 reviews * 2 reviews *
Moderate Low to Moderate Moderate
Safety:
• Pregnancy and delivery
complications
5 reviews 1 review 3 reviews 5 reviews 2 primary studies 1 review
Very Low to Low Very Low to
Moderate
Low to Moderate Very Low to Moderate Low Low to Very Low
• neonatal/infant complications 15 reviews * 2 reviews 3 reviews 2 primary studies 1 review
Very Low to Low Low to Moderate Low to Moderate Low Low to Very Low
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stage embryos to fresh cleavage-stage embryos or SC
(1 RCT, 12 retrospective cohorts, and 12 registry reports)
[44]. The remaining 42 were non-comparative and evalu-
ated the transfer of frozen blastocyst-stage embryos or the
fertilization and transfer of frozen oocytes. In most, details
of clinical protocols used were not reported. No reviews
or additional primary studies reporting the effect of fresh
versus frozen embryo transfer on the incidence of multi-
ples were found.
Stage of embryo during transfer
Four meta-analyses focused on the effect of developmental
stage of the embryo during transfer, comparing cleavage-
stage embryo transfer, where embryos were transferred 2–3
days after fertilization, to blastocyst-stage embryo transfer,
where embryos were transferred 5–6 days after fertilization
[47-51]. Three limited inclusion to RCTs. The fourth in-
corporated any comparative study reporting on sex ratio
and monozygotic twinning (MZT), regardless of its design.
All 4 meta-analyses considered fresh cycles only, and in 2,
autologous oocytes only. Collectively, they involved a total
of 38 distinct primary studies (18 RCTs) published be-
tween 1987 and 2007. Across these studies, there was little
difference in COS protocols reported (mainly GnRHa +
hMG and/or FSH), and in most, the use of donor oocytes
was not explicitly mentioned, nor was the number of
embryos per cycle or the number of cycles per woman.
Where reported, numbers varied across studies. In 9, only
women deemed likely to succeed with blastocyst transfers
were included, and in 2, only women with a poor progno-
sis were included. The rest of the studies involved ‘unse-
lected’ couples where only maternal upper age limits
ranging from 35 to 44 years had been applied. Safety data
were limited. However, 2 primary studies (retrospective
cohorts published in 2012 and 2013) which assessed the
impact of embryo stage on obstetric and perinatal compli-
cations after IVF provided such information [52,53].Figure 3 Quality of systematic reviews: Oxman and Guyatt index of sDonor embryo transfer
One systematic review assessing the safety of IVF/ICSI
using donor embryos was included [54]. Details of the
79 primary studies covered in the review were not pro-
vided. A review of the clinical effectiveness of donor IVF
in comparison to autologous IVF was not found. There-
fore, one recent primary study assessing the effectiveness
of donor IVF/ICSI in 6 countries with national ART sur-
veillance programs was included [55]. The study com-
pared data from over 1 million autologous IVF cycles to
over 100,000 donor cycles across Australia/New Zealand,
Canada, Finland, the UK, and the US [55]. No reviews
or additional primary studies assessing the impact of
donor embryo transfer on cycle cancellation or multiple
births were found.
Overall quality of included studies
Results of quality assessment for the systematic reviews
are presented in Additional file 5: Table S5 and Figure 3.
In general, most of the systematic reviews were of high
quality, regardless of whether meta-analyses had been per-
formed. All provided details of their search strategy, which
was comprehensive, and nearly all clearly described their
study inclusion criteria. Aside from one review that ex-
cluded studies with 0% incidence of a primary outcome,
no clear bias in study selection was found. The most com-
mon weakness of the reviews was failure to perform or
report a validity assessment of included studies (12/33).
However, where validity was assessed, appropriate criteria
were used. Of reviews with meta-analyses (24/33), all re-
corded methods used to combine outcomes data, and all
were appropriate. Comparing studies that pooled data
with those that did not, there was variation in the degree
of clinical heterogeneity deemed too much to pool. Con-
clusions drawn in all reviews were consistent with the data
they collected and reported.
The overall rating of the quality of evidence according
to the GRADE scale for each comparison and outcomecientific quality for systematic reviews.
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comparisons addressed in the reviews and additional pri-
mary studies, data from experimental trials were available
and supplemented with data from prospective and retro-
spective cohorts. Studies assessing the effectiveness of
IVF/ICSI in comparison to spontaneous conception and
less invasive ARTs were of ‘moderate’ quality. Similarly,
the available evidence on the effectiveness of IVF/ICSI by
the stage of embryo transferred was ‘moderate’, while both
‘low’ and ‘moderate’ quality studies comprised the body
of evidence on the effectiveness of IVF/ICSI by the num-
ber and state (fresh or frozen) of embryos transferred. With
respect to pregnancy and delivery complications, some
‘moderate’ studies were available. However, most of the
evidence was ‘low’ quality. The poorest quality data were
around infant outcomes after ARTs compared to SC
(mostly ‘very low’ quality, some ‘low’ quality). They
originated from small studies that typically compared
ART-conceived infants to either the general population or
‘spontaneously’ conceived infants. Therefore, it was diffi-
cult to rule out the use of less invasive ARTs treatments in
control groups, as well as the potential influence of infer-
tility and other population differences.
Within each review, patient populations and treat-
ments varied across included studies. Among reviews of
the same comparisons, there was overlap in selected
studies (multiple reports on the same studies or patients
published by different investigators). The majority of re-
views did not identify or discuss such overlap.
Safety
IVF/ICSI in comparison to SC
Pregnancy/delivery complications In two reviews, in-
creased risks of ectopic pregnancy (EP) (10% vs. 2%),
gestational diabetes (GD) (10% vs. 6%), pregnancy-
induced hypertension (PIH) (6% vs. 3%), placenta praevia/
placental abruption (4% vs. 1%), preterm premature rup-
ture of membranes (proportions not reported), caesarean
delivery (proportions not reported), and preterm delivery
(PTD) (8% vs. 5%) were observed in women who under-
went IVF/ICSI with SET or achieved a singleton pregnancy
through IVF/ICSI compared to those who conceived ‘spon-
taneously’ [29,30]. These risks remained even after studies
with spontaneous pregnancies in infertile couples had been
excluded through sensitivity analyses.
A significant increase in the risk of preterm birth
(PTB) after IVF/ICSI in comparison to SC was further
confirmed in 4 meta-analyses of studies controlling for
at least maternal age, among other potential confound-
ing factors [20,22,23,32]. Across the studies that controlled
for basic maternal characteristics (e.g., age, parity), women
who conceived twins through ARTs were more likely
to undergo a caesarean section delivery than women
who conceived twins spontaneously (OR:1.7) [20]. Thoseadjusting for at least maternal age indicated that single-
tons born to infertile women without the use of assisted
conception had a significantly higher risk of PTB and
low birth weight (LBW) than singletons born to fertile
women [32].
Infant/neonatal complications Indirect comparisons in
1 review showed MZT rates following ARTs approached
2%, which was over double that found after SC (0.4%)
[25]. This rate was further amplified in FETs (3%) and
blastocyst embryo transfers (5%). Pooled data from re-
views controlling for at least maternal age in singletons
and twins separately revealed a significantly increased odds
of being born LBW after IVF/ICSI in both groups, with a
more distinct effect in singletons (OR:1.6-singletons/1.1-
twins) [22,23,29]. Furthermore, IVF/ICSI singletons, but
not twins, were small for their gestational age compared
to SC singletons and twins (OR 1.5). In another analysis of
twins only, no significant differences in LBW, neonatal in-
tensive care unit (NICU) admission, or perinatal mortality
(PNM) rates were seen between IVF/ICSI twins and SC
twins, with the exception of a subgroup of twins of differ-
ent sexes [20]. Conversely, singletons conceived through
IVF/ICSI were at almost double the risk of PNM and 1.6
times the risk of NICU admission than singletons con-
ceived spontaneously (p < 0.05) [29].
Across reviews, birth defect and congenital malforma-
tion rates in infants born after IVF/ICSI were signifi-
cantly higher than those in SC infants (pooled OR:1.3-2.0),
while no differences in imprinting disorders were noted
[19,20,26,28,29,33]. When ART singletons and multiples
had been considered separately, congenital malforma-
tion rates were significantly higher in both groups (OR:
singletons-1.7/multiples-6.7) compared to SC singletons
and multiples, but birth defect rates were no different be-
tween ART multiples and SC multiples.
Three reviews reported that couples who conceived via
IVF/ICSI were over twice as likely to have an infant with
cerebral palsy, in comparison to couples who conceived
naturally [24,27,35]. This difference held for singletons,
while no significant differences between twins were ob-
served. Evidence around the risk of autism spectrum dis-
orders (ASD) in IVF/ICSI children was variable. In one
review, 3 of 5 studies found no differences between IVF/
ICSI conceived and SC infants, one reported a significant
increase in the incidence of a broader group of psychiatric
disorders (of which 1 disorder was ASD) in IVF/ICSI chil-
dren, and one showed significantly reduced chances of
having ASD following IVF, after adjusting for several fac-
tors [24].
Among studies included across 4 reviews that assessed de-
velopmental delay, most reported no significant differences
in motor (15/17 studies), emotional/behavioral (14/19),
cognitive (11/15), or mental (10/11) development between
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pared to SC [24,27,34,35]. Similar growth patterns be-
tween ART-conceived and spontaneously conceived
children, adolescents, and adults were observed [21,34].
Chronic disease profiles in children and adolescents were
also similar, with the exception of a higher prevalence
of attention-deficit/hyperactivity disorder, depression,
binge drinking, and cancer after ARTs, which were re-
ported in one study [35].IVF/ICSI in comparison to less invasive ARTs treatment
options
Pregnancy/delivery complications One review com-
pared the incidence of ovarian hyperstimulation syndrome
(OHSS) in women undergoing IVF to that in women
undergoing IUI with COS, and found no difference [31].
In a review of hypertensive complications, after adjusting
for age and smoking status among other factors, women
who conceived through IVF/ICSI/GIFT/ZIFT, but not
ovulation induction or IUI, were significantly more likely
to have preeclampsia than women who conceived spon-
taneously (OR:1.8-2.7) [36]. However, where analyses had
controlled for maternal age, gestational age and parity, the
odds of experiencing GD, PIH, and caesarean delivery
were found to be significantly higher not only after IVF
but also after IUI in comparison to SC [36].Neonatal/infant complications In a single review of
rates of congenital malformations, no significant differ-
ences between women who conceived through ovulation
induction with or without IUI and those who conceived
spontaneously were found [28] However, IUI was not
compared to IVF/ICSI.Number of embryos transferred
Pregnancy/delivery complications The results of one
meta-analysis indicated that compared to SET, DET was as-
sociated with higher rates of preterm rupture of mem-
branes (8.5%), placental abruption (2.2%), and preeclampsia
(7.7%) (compared to 0.8%, 0%, 7.0%, respectively; statistical
significance not reported) [30]. With respect to the inci-
dence of GD, findings were inconsistent. No significant
differences between SET and DET in ectopic pregnancy
and placenta praevia were found [30,38].
Findings from a meta-analysis of RCTs showed a sig-
nificantly lower risk of PTD after SET in comparison to
DET (OR:0.3-0.4) [30,37]. However, those from a meta-
analysis of cohort studies showed no significant differ-
ence [30,37]. Further, in one cohort study included in
this review, more women underwent caesarean section
delivery after DET (24%) compared to SET (20%) (sig-
nificance not reported).Neonatal/infant complications The results of two re-
views indicated that infants born after IVF/ICSI with SET
were 2–4 times less likely to be born LBW compared to
infants born after DET (pooled OR:0.3-0.5) [30,37]. In one
of the reviews, a single RCT reported higher rates of neo-
natal mortality (NNM) (1.1% vs. 0%), PNM (1.0% vs.
0.7%), and congenital malformations (4.8% vs. 3.1%) after
DET (significance not reported), while pooled data from
cohorts demonstrated no significant difference in neonatal
or PNM, or NICU admissions between SET and DET [30].
Fresh versus FET
Pregnancy/delivery complications In two reviews, no
significant differences in the number of ectopic pregnan-
cies or women admitted to the hospital during their
pregnancy after fresh versus FETs were observed [42,43].
One review included a study in which slightly more women
developed OHSS after fresh versus FET, but differences did
not reach statistical significance. In meta-analyses limited
to singleton pregnancies, a significantly lower incidence of
antepartum hemorrhage and PTB after FET (9% and 3%,
respectively) compared to fresh embryo transfer (11% and
5%, respectively) was found [45]. However, the incidence
of caesarean delivery after frozen cycles was significantly
higher (35% vs. 29%) [45]. Combined data from singletons
demonstrated significantly lower PTB rates after FET in
comparison to fresh embryo transfer (RR:0.9), but for
twins, the results varied [32,44].
Neonatal/infant complications In singletons born after
IVF/ICSI, FETs were consistently associated with a lower
risk of LBW than fresh embryo transfers (pooled RR:0.69)
[45]. For twins, three studies included in a review reported
a reduced incidence of LBW after FETs (38-47%) com-
pared to fresh transfers (50-55%), while two found no dif-
ference [44].
Two reviews indicated that the rates of stillbirths and
NICU admissions after FET were lower and similar, re-
spectively [44,45]. Further, pooled data in one review
showed no significant differences in congenital malfor-
mations between fresh and FET [45]. Long-term growth
patterns were normal and similar between fresh IVF/
ICSI infants and frozen IVF/ICSI infants, and between
these 2 groups and a group of SC controls [44]. Con-
versely, early delays in growth were demonstrated in
both fresh and frozen IVF/ICSI groups in comparison to
SC multiples. However, these differences dissipated after
6 months of age.
Stage of embryo during transfer
Pregnancy/delivery complications One of 9 compara-
tive studies comprising a review showed significantly
higher rates of MZT after blastocyst transfers compared to
cleavage transfers [47]. Other than this finding, no review
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cleavage-stage embryo transfers. Two recent primary
studies, one on over 12,000 singleton IVF births from a
Canadian ART registry and one on over 4,000 singleton
IVF births in Australia, performed analyses of obstetric
and perinatal complications, adjusting for several maternal
and procedural characteristics [52,53]. No significant differ-
ences in preeclampsia, antepartum/postpartum hemorrhage,
placenta previa, placental abruption, after blastocyst ver-
sus cleavage-stage transfers were seen. However, one
found higher chances of PTB associated with blastocyst-
stage transfers (17%) in comparison to cleavage-stage
transfers (14%; OR:1.3; p < 0.001) [53].
Neonatal/infant complications In the two primary stud-
ies reporting infant outcomes, no significant differences in
LBW, size for gestational age, congenital anomalies, still-
birth, or neonatal death blastocyst- and cleavage-stage
embryo transfers were found [52,53].
Donor embryo transfer
Pregnancy/delivery complications One systematic re-
view demonstrated that, in comparison to autologous IVF/
ICSI cycles, first trimester vaginal bleeding and hyperten-
sive complications were significantly higher in pregnancies
resulting from donor IVF/ICSI cycles (even when age and
parity were taken into account), in 2 and 5 studies, re-
spectively [54]. No significant differences between donor
cycles and PTD were observed [54].
Neonatal/infant complications The same review found
no significant differences in LBW rates, proportion of in-
fants small for their gestational age, or congenital malfor-
mation rates between infants conceived through donor
IVF versus those conceived through autologous IVF [54].
Efficacy/effectiveness
IVF/ICSI in comparison to SC
Pregnancy and live births Based on a meta-analysis of
2 RCTs, the odds of achieving a clinical pregnancy after
1 cycle of IVF were over 3 times higher than those after
3–6 months of no treatment [31]. Further, very few cou-
ples (4%) with unexplained infertility had a live birth
after 3–6 months of no treatment, whereas almost half
of couples with unexplained infertility achieved a live
birth after 1 cycle of IVF (OR:22.0).
IVF/ICSI in comparison to less invasive ARTs treatment
options
Pregnancy and live births Results from one meta-analysis
indicated no significant differences in pregnancy or live
birth rates after IVF and stimulated IUI (sIUI) in couples
with unexplained infertility. However, to achieve the same
pregnancy and live birth rates rates, up to 3 cycles of IUIwere required, compared to 1 cycle of IVF [31]. In con-
trast, pregnancy and live birth rates were significantly dif-
ferent between IUI and IVF when IVF was used as a
second line of treatment in couples who were unable to
succeed with 3 cycles of IUI with CC (84% of women be-
came pregnant within 6 cycles of IVF (19% miscarriages)
in comparison to 30% of women within 3 cycles of IUI
with FSH (14% miscarriages) (OR:12.8-pregnancy/2.7-live
birth)).
Multiple pregnancies/births The same meta-analysis
demonstrated similar multiple pregnancy rates after sIUI
and IVF. However, multiple pregnancies in the IVF group
were found to occur only in couples who received more
than 1 embryo [31]. Further, multiple pregnancy rates ap-
peared to be lower after 1 cycle of elective SET IVF (14%)
compared to 3 cycles of IUI (25%), but statistical signifi-
cance was not reported.
Number of embryos transferred
Cycle success Both reviews examining the relationship
between number of embryos transferred and number suc-
cessfully implanted found that success rates were similar,
regardless of whether 1 or 2 had been transferred [38,39].
Pregnancy miscarriages and live births In contrast,
clinical and ongoing pregnancy rates per couple after DET
were shown to be almost 2 times greater than pregnancy
rates after SET, even where only women under 36 years of
age were considered (pooled RR:1.4-2.2, 1.9-2.1, respect-
ively) [38-40]. In another review, significantly higher preg-
nancy rates were seen in women who received more than
two embryos in comparison those who received one or
two embryos [41]. Further, in a single small RCT included
in one of the reviews which compared women undergoing
one IVF/ICSI cycle with DET to those undergoing 2 SET
cycles (one fresh SET cycle and one frozen SET cycle), one
three embryo transfer (TET) cycle, or one four embryo
transfer (QET) cycle, no differences in clinical pregnancy
rates were observed [40]. In most of the reviews, the risk
of miscarriage between DET and SET or eSET groups was
shown to be similar [30,37,38,40].
Based on the results of meta-analyses, while cumulative
live birth rates per couple were found to be comparable
between DET and SET, live birth rates per cycle after DET
were significantly higher than those after SET, with odds
ratios ranging from 1.6-2.1, after adjusting for the cause of
infertility, treatment characteristics, and the quality of em-
bryos transferred [37-40]. This effect did not change dur-
ing subgroup analyses of individual patient data comparing
women under 33 years of age to those 33 and older, cou-
ples with less than 3 years of infertility to those with 3 or
more years of infertility, and top quality embryos to lesser
quality embryos [37]. The probability of a live birth was
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DET (13% and 29%, respectively), but differences did not
reach statistical significance.
Multiple pregnancies/births In one meta-analysis of 8
RCTs, the odds of carrying multiples were found to be
greater in women who achieved a clinical pregnancy
through DET than in women who received SET/eSET
(19%-30% vs. 1%-2%; OR:17–25; p < 0.05) [40]. In 1 of
the RCTs included in this analysis, the incidence of mul-
tiples was also higher in TET compared to DET (RR:0.17
(0.01, 3.85)), QET compared to DET (RR:0.4 (0.1, 2.0)),
and after 1 cycle of DET compared to 2 cycles of SET
(RR:0.02-0.06) [37,38,40]. Findings were consistent regard-
less of maternal age (<33 or ≥33), duration of infertility
(<3 or ≥3), or embryo grade (A or B).
Fresh versus FET
Pregnancy and miscarriages In contrast to the results
of an earlier review including only 1 RCT, the results of
a recent pooled analysis of 3 RCTs found that clinical
and ongoing pregnancy rates, but not miscarriage rates,
were significantly higher after frozen compared to fresh
IVF/ICSI cycles (RR:1.31, 1.32, respectively) [43,46].
Stage of embryo during transfer
Cycle success Two meta-analyses of 7 and 11 RCTs found
that significantly fewer embryos were cryopreserved
(41-53% vs. 63-71%; OR:0.3-0.5) and more women can-
celled their cycle or failed to transfer any embryos (9% vs.
3-5%; OR:2.2-2.9) after blastocyst-stage embryo trans-
fers than after cleavage-stage embryo transfers, even in
studies where more cleavage-stage embryos were trans-
ferred [48,50].
Pregnancy miscarriages and live births In the same
two meta-analyses, slightly higher clinical pregnancy rates
were demonstrated after IVF/ICSI with blastocyst-stage
embryos (39-40%) compared to cleavage-stage embryos
(34-39%) [48,50]. While these differences were significant
in one (OR:1.3), the other only found significant differ-
ences in cumulative clinical pregnancy rates after all fresh
and frozen IVF/ICSI cycles. Further, subgroup analyses re-
vealed no differences when an equal number of cleavage
and blastocyst stage embryos were transferred, or when
more cleavage stage embryos than blastocyst stage em-
bryos were transferred. No variation in the proportion of
women experiencing miscarriages after blastocyst trans-
fers versus cleavage transfers was found [50].
Further, these meta-analyses also demonstrated that
IVF/ICSI with blastocyst-stage embryos was associated
with a higher likelihood of a live birth than IVF/ICSI with
cleavage-stage embryos (pooled OR: 1.4 (1.1, 1.8)) [48,50].
When only women expected to have a good prognosiswith blastocyst transfer were considered, differences were
even greater, and, conversely, when unselected women or
women with a poor prognosis were considered, no signifi-
cant differences were shown.
Multiple pregnancies/births No significant difference
in the multiple pregnancy rates between blastocyst- and
cleavage-stage embryo transfers were seen [48,50].
Donor embryo transfer
Live births No reviews discussed differences in effective-
ness between donor and non-donor IVF. In a recent pri-
mary study of IVF/ICSI in 6 countries, in comparison to
autologous IVF/ICSI (31%), live birth rates were slightly
lower if donor embryos (28%) or frozen donor oocytes
(27%) were used (RRs: 0.90 (0.87,0.93) and 0.90 (0.89,0.92),
respectively), and significantly higher if fresh donor oocytes
were used (47%; OR:1.50 (1.49,1.52)) [55].
Multiple pregnancies/births In the same primary study,
while no statistical comparisons were performed, multiple
birth rates after fresh autologous IVF/ICSI were 17.2%,
30.3%, and 33.0% in Australia/New Zealand, Canada, and
the US respectively, whereas multiple birth rates after
IVF/ICSI with donor embryos were 16.1%, 24.9%, and
27.1% respectively [55].
Discussion
This review summarizes the current state of the science
around the safety and effectiveness of IVF/ICSI in com-
parison to spontaneous conception and less invasive
ARTs and the impact of certain procedural factors on the
safety and clinical effectiveness of IVF/ICSI for the treat-
ment of infertility. This study was conducted to support
policy development by the provincial government of
Alberta. As public policy is usually context-dependent,
the comparators chosen for this study were based on the
ARTs interventions under consideration for funding in the
province and the corresponding policy questions around
the funding of these interventions. They did not include
comparisons of the different drug regimens used or treat-
ment ‘add-ons’, such as preimplantation genetic diagnosis
or assisted hatching, as these considerations were not
within the scope of the policy questions outlined by the
provincial government.
In comparison to SC, IVF/ICSI appears to be associ-
ated with an increased risk of various complications oc-
curring during pregnancy and delivery. It may also have
adverse effects throughout infancy, childhood and adult-
hood. However, these trends could be due to increased
surveillance in IVF/ICSI pregnancies, infertility itself, or
maternal complications, and, the growth and development
of the offspring still appears to follow normal patterns.
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findings.
Evidence compiled to date suggests that compared to
SET, IVF/ICSI with DET is associated with more adverse
events during pregnancy and delivery and safety issues in
infants. However, embryo stage (blastocyst versus cleav-
age) does not appear to impact safety. Similarly, the health
of infants born after donor cycles appears to be at least as
good as that of infants born after autologous cycles. How-
ever, donor IVF is often associated with anovulation and
advanced maternal and studies of donor cycles should
take both of these factors into account. In comparison to
fresh embryo transfer, the findings suggest that FET has
fewer adverse events throughout pregnancy and delivery,
and is least as safe as fresh embryo transfer in terms of in-
fant outcomes.
Overall, IVF shows a clear benefit over no treatment
and IUI for certain types of infertility with respect to
pregnancy and live birth. Clinical pregnancy rates after
IVF/ICSI do not appear to be influenced by the use of
ICSI over IVF, although the differences in populations pre-
dicted to benefit from ICSI in comparison to IVF have not
been thoroughly assessed. In fact, most of the studies
comprising the review did not specifically address this
point. The findings suggest that clinical pregnancy rates
and live birth rates are similar or better after FET com-
pared to fresh embryo transfer, and after blastocyst-stage
embryo transfer compared to cleavage-stage embryo trans-
fer, particularly in women considered to have a good prog-
nosis. There appears to be little if any difference in the rate
of multiple pregnancies between the two groups. DET cy-
cles, rather than SET cycles, may greatly improve both
pregnancy and live birth rates, but substantially increase
the probability of a multiple pregnancy/birth. The same
improvements in likelihood of pregnancy and live birth
seen with DET and no increase in multiple birth rates ap-
pear to be achievable through 2 cycles of SET or 1 fresh
SET cycle and 1 frozen SET cycle. Further, regardless of
whether 1 or 2 embryos are implanted, IVF/ICSI with top
quality embryos seems to yield better live birth rates than
do less than top quality embryos.
Conclusions
The safety of IVF/ICSI depends, in part on procedural
choices made. However, these choices may reduce its ef-
fectiveness. Therefore, clinical and policy guidance need
to ensure that the trade-offs involved are carefully con-
sidered by both patients and providers.Additional files
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